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Abstract
Purpose: An aggressive trimodality approach from the Minnie Pearl Cancer Research Network
[carboplatin AUC = 6, days 1 and 22; 5-fluorouracil 225 mg/m2 continuous infusion, days 1–42,
paclitaxel 200 mg/m2, days 1 and 22; 45 Gy] has resulted in remarkable pathologic response rates
but notable toxicity. This trial was designed to mitigate this toxicity by starting with a lower
carboplatin dose, AUC = 4, and by adding subcutaneous amifostine.
Methods: This phase II trial included patients with locally advanced, potentially resectable
esophageal cancer. All were to receive the above regimen with modifications of carboplatin AUC
= 4 and amifostine 500 mg subcutaneously before radiation. All were then to undergo an
esophagectomy. A planned interim toxicity analysis after the first 10 patients was to determine
whether the carboplatin dose should escalate to AUC = 6.
Results: Ten patients were enrolled, and all required dose reductions/omissions during
neoadjuvant therapy. One patient died from paclitaxel anaphylaxis. Six patients manifested a
complete pathologic response.
Conclusion: With this regimen, carboplatin AUC = 4 for patients with locally advanced
esophageal cancer is appropriate.
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locally advanced esophageal cancer [1,2]. Particularly
noteworthy are data from Meluch and others from the
Minnie Pearl Cancer Research Network [3]. These investi-
gators published an innovative trial that examined neoad-
juvant therapy that consisted of the following: carboplatin
area under the curve (AUC) of 6 on days 1 and 22, paclit-
axel 200 mg/m2 days 1 and 22, 5-fluorouracil 225 mg/m2
per day by continuous infusion days 1–42 along with
radiation 45 Gy in 25 fractions. Yielding some of the most
remarkable response rates observed in the treatment of
esophageal cancer, this regimen resulted in a pathologic
complete response rate of 46% within an initial cohort of
37 patients. Although long-term survival had not been
reported, these data appear promising when one acknowl-
edges that pathologic complete response predicts a longer
survival and better prospect for cure for patients with this
malignancy [4]. Moreover, recent preliminary data suggest
that these response rates are reproducible [5,6].
However, this high complete response rate occurred at the
expense of substantial treatment-related toxicity. During
neoadjuvant therapy, grade 3 or worse leukopenia
occurred in 65% of patients. Twenty-two percent of
patients required hospitalization for neutropenic fevers.
Grade 3 or worse esophagitis occurred in 31%. Over half
of patients suffered weight loss of 10 pounds or more dur-
ing neoadjuvant therapy. Finally, although there were no
deaths during the administration of neoadjuvant therapy,
the postoperative death rate was 9%.
These toxicity data, coupled with these high response
rates, underscore the need to test such novel, aggressive
treatments in conjunction with methods to mitigate toxic-
ity. This report describes the planned interim toxicity
analysis from an ongoing North Central Cancer Treat-
ment Group (NCCTG) trial that was undertaken with this
goal in mind. The NCCTG trial employed two modifica-
tions to the Minnie Pearl Regimen in an attempt to miti-
gate toxicity: 1) carboplatin dosing was reduced from
AUC = 6 to AUC = 4 in the first 10 patients with the pos-
sibility of dose escalation thereafter; 2) amifostine 500 mg
subcutaneously to be given before radiation, as prompted
by data from Koukourakis and others [7] as well as by
other subsequent reports [8]. An interim analysis of toxic-
ity in this NCCTG trial was planned after enrollment of
the first 10 patients to decide whether to continue this
trial and, if so, whether to escalate the carboplatin to AUC




This trial was initiated and conducted within the NCCTG.
The Institutional Review Boards at each site approved the
protocol before patient enrollment, and all patients pro-
vided signed informed consent at the time of enrollment.
Eligibility and Exclusion Criteria
Eligibility criteria consisted of the following: 1) age ≥ 18
years; 2) histologic or cytologic evidence of squamous cell
carcinoma or adenocarcinoma of the esophagus; 3) surgi-
cally resectable tumor, as deemed by a surgeon; 4) Eastern
Cooperative Oncology Group (ECOG) performance score
of 0–2; 5) anticipated life expectancy of ≥ 12 weeks; 7) the
laboratory parameters < 14 days prior to registration of
absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥
100 × 109/L, total bilirubin ≤ 1.5 times the upper limit of
normal, serum creatinine ≤ 1.5 times the upper limit of
normal, asparatate aminotransferase ≤ three times the
upper limit of normal.
Exclusion criteria consisted of the following: 1) uncon-
trolled infection; 2) prior chemotherapy for esophageal
cancer; 3) pregnancy or unwillingness to utilize contra-
ception if pregnancy was a possibility; 4) New York Heart
Association classification III or IV; 5) other severe under-
lying illness that, in the opinion of the treating oncologist,
would make the patient inappropriate for study entry; 6)
prior radiation that would overlap anticipated radiation
fields; 7) antihypertensive or diuretic medications that
could not be safely discontinued, if necessary, for several
days during study treatment.
Treatment Regimen
The neoadjuvant treatment regimen consisted of both
chemotherapy and radiation. Chemotherapy consisted of
carboplatin with an area under the curve (AUC) of 4 to be
given intravenously on days 1 and 22, paclitaxel 200 mg/
m2 to be given intravenously on days 1 and 22, and 5-
fluorouracil 225 mg/m2/day to be given by continuous
intravenous infusion on days 1 through 42. In addition,
amifostine was to be administered as a 500 mg flat dose
subcutaneously immediately before each radiation
treatment.
For evaluation purposes, a treatment "cycle" is defined by
the administration of carboplatin and paclitaxel, where
the initiation of these agents heralded the start of a new
chemotherapy "cycle." In effect, cycle 1 occurred during
days 1–21 of the treatment, and cycle 2 between days 22–
42.
The protocol was written to allow for a dose increase of
carboplatin to an AUC of 6 in the event that a planned
interim toxicity analysis after the first 10 patients deemed
this increase could be undertaken safely.Page 2 of 5
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Each fraction size was 180 centigray, and a total of 25 frac-
tions were to be given.
Chemotherapy dose reductions were initiated based on
toxicity. As determined by the National Cancer Institute's
Common Toxicity Criteria (NCI CTC), version 2, Grade 3
or worse stomatitis, esophagitis, or diarrhea prompted
holding 5-fluorouracil until symptoms were grade 2 or
better. If treatment was held for diarrhea, the protocol
called for resuming the continuous infusion 5-fluorour-
acil at 80% of the prior dose. 5-Fluorouracil that was held
was not to be made up. Severe myelosuppression on
weekly blood counts (absolute neutrophil count ≥ 0.5 ×
109/L for greater than 2 days and/or platelet count ≤ 25 ×
109/L) prompted a 25% dose reduction of both paclitaxel
and carboplatin on day 22. Similarly, on day 22, the pro-
tocol mandated that paclitaxel and carboplatin be held
until the absolute neutrophil count was ≥ 1.5 × 109/L and
the platelet count ≥ 100 × 109/L. For grade 3 or worse
esophagitis, the paclitaxel and carboplatin were held until
the esophagitis resolved to grade 1 or less. Paclitaxel was
also held for grade 3 or worse neuropathy. Re-treatment
was permitted with a 30% dose reduction in the event the
neuropathy resolved to grade 2 or better. For any grade 3
or 4 event attributable to amifostine, the amifostine was
to be decreased to 300 mg and subsequently discontinued
if the event recurred at the lower dose. Finally, radiation
was to be held for myelosuppression (absolute neutrophil
count < 1.0 × 109/L and/or the platelet count < 50 × 109/
L) or for grade 4 esophagitis.
Aggressive supportive care measures were recommended
throughout the neoadjuvant portion of the regimen.
These measures included, but were not limited to, pre-
medication with corticosteroids prior to paclitaxel, use of
antiemetics before and during chemotherapy and before
amifostine, and nutrition and hydration support, as
needed.
An esophagectomy was to be performed within 4–8 weeks
after completion of radiation for all patients still deemed
to be operative candidates.
The protocol also included an optional, additional two
cycles of post-operative chemotherapy with paclitaxel and
carboplatin with dosing, for the most part, left to the dis-
cretion of the treating oncologist.
Pretreatment and Follow Up Evaluations
All patients underwent a history and physical examina-
tion within 21 days of trial registration. Other testing was
performed within this time frame as well and included a
complete hemogram, chemistry profile, computed tom-
ography scan or magnetic resonance imaging of the chest
and abdomen, chest radiograph, electrocardiogram, and
an esophagoscopy. A bone scan was required if the alka-
line phosphatase was two times the institution's upper
limit of normal, and a bronchoscopy was required if the
primary tumor was adjacent to the trachea or left main
stem bronchus or if the patient was experiencing respira-
tory symptoms. Other testing was optional and included
endoscopic ultrasound of the upper gastrointestinal tract
and positron emission tomography scanning.
All patients were monitored throughout the period of
radiation and chemotherapy administration with a
weekly history and physical examination and weekly
hemograms. History, physical examination, hemogram
and chemistry profiles were mandated before days 1 and
22 of chemotherapy.
Tumor assessments were performed two weeks prior to
surgery, and RECIST criteria, as recommended by the NCI
http://www.nci.nih.gov/bip/RECIST.htm, were used to
determine tumor response [9]. Additionally pathological
response was assessed post-operatively.
Other testing, such as quality of life assessment and geno-
typing, were also obtained but will be reported at a later
date.
Statistical Analyses
The purpose of this study was to assess the safety of this
treatment regimen for patients with locally advanced
esophageal cancer. The protocol called for a three-stage
phase II study design with a safety analysis in the first 10
patients. The first 10 patients received treatment, as
described above, with a carboplatin AUC = 4. It was
decided a priori that if more than two of the initial patients
developed grade 4 or 5 non-hematologic adverse events
during neoadjuvant therapy or died within 15 days of sur-
gery, then the study would not permit a carboplatin dose
increase to an AUC = 6.
All data on toxicity and response are presented descrip-
tively in this initial 10-patient report on the first phase of
this trial. Summary statistics, including means and
median values, frequency tables, and graphical methods
were used to describe the distributions of drug adminis-
tration, clinical characteristics, and adverse event rates.
Unless otherwise specified, all adverse event data are
reported regardless of relationship to study treatment.
Results
Demographics
Ten patients were recruited from late April 2001 to early
March 2002. Patient characteristics are listed in Table 1,
which shows that the median age of the cohort was 63
years (range 49–81) and that nine patients had an EasternPage 3 of 5
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score of 1.
Drug Administration
During administration of neoadjuvant therapy, all 10
patients required a dose reduction or an omission of drug
administration because of treatment-related toxicity
(Table 2). Overall, nine patients received both cycles of
neoadjuvant chemotherapy.
Toxicity
Severe adverse events during neoadjuvant therapy con-
sisted of 1 death (paclitaxel-related allergic reaction); 15
grade 4 events (myelosuppression (11); mucositis (1);
dyspnea (1); neutropenia (1); and cerebral vascular acci-
dent (1); and 55 grade 3 events of various types (Table 3).
Six of eight patients experienced grade 3 or greater adverse
events within 15 days of surgery, and four of these were
grade 4 events. Some patients experienced more than one
event. Specifically, two patients suffered acute respiratory
distress syndrome; one patient thrombophlebitis; two
patients dyspnea; one patient non-specific constitutional
symptoms; one patient neutropenia; and one patient a
dysrhythmia. Of the two patients with acute respiratory
distress syndrome, one remains alive 6 months after sur-
gery as of this report, and the other died roughly 3 months
after surgery.
Preliminary Response Data
A total of 9 patients underwent an esophagectomy, dem-
onstrating 6 complete pathologic responses.
Discussion
This report describes a planned interim toxicity analysis of
the first 10 patients who were enrolled on a multi-institu-
tional trial for patients with locally advanced esophageal
cancer. This NCCTG trial tested a version of the Minnie
Pearl Regimen with two main modifications: a drop in the
carboplatin AUC dose from 4 to 6 and an addition of ami-
fostine 500 mg subcutaneously (flat dose) prior to each
dose of radiation. Preliminary analyses show that this
modified regimen resulted in a substantial rate of severe
toxicity: one death from a paclitaxel allergic reaction, sev-
eral episodes of grade 4 neutropenia/leukopenia, one
episode of grade 4 mucositis as well as several grade 3
events – all of which were attributable to the study regi-
men. At the same time, however, this regimen resulted in
6 of 10 patients manifesting a complete pathologic
response. The results of this planned analysis led to the
NCCTG's decision to reopen this trial with a carboplatin
dose of AUC = 4. In effect, the results of this interim anal-
ysis suggest that oncologists who might choose to treat
patients with the Minnie Pearl Regimen should consider
treating with this lower carboplatin dose, especially
should they choose to include amifostine for its purported
cytoprotective effects.
In fact, a major modification of the Minnie Pearl Regimen
in the NCCTG trial described here is the addition of sub-
cutaneous amifostine. It remains unclear whether the
Table 1
Characteristic N = 10






Patient Amifostine dose received (%)* Neoadjuvant chemotherapy dose received (%) 1stcycle/2ndcycle* Disease Status
1 31 81/75 CR**
2 7 71/57 CR
3 16 64/11 PR***
4 27 100/26 PR
5 73 100/100 CR
6 24 52/3 CR
7 63 62**** PR
8 87 86**** dead
9 7 91/28 CR
10 67 72/79 CR
*denotes the lowest percentage of administered drug for a cycle
** complete response (CR)
***partial response (PR)
****second cycle not givePage 4 of 5
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icity observed in this trial. Certainly, the inclusion of ami-
fostine into this regimen did not permit a dose escalation
of carboplatin to an AUC of 6, as tested in the original
Minnie Pearl Regimen. Although amifostine is considered
cytoprotective, it also carries toxicity in its own right
including nausea, vomiting, and hypotension. Prelimi-
nary data suggest that subcutaneous administration of
amifostine might be better tolerated than intravenous
administration, but these conclusions are not based on
large, comparative studies. The fact that the amifostine,
carboplatin, 5-fluorouracil, paclitaxel, and radiation were
all given in combination as part of the phase II study pre-
sented here makes it impossible to sort out attribution as
it pertains to an individual study agent, such as amifos-
tine. Should the results of this trial continue to appear
promising, a larger phase III trial would be necessary to
provide a definitive answer on the contribution of subcu-
taneous amifostine to the efficacy and toxicity profile of
this regimen.
In short, the preliminary toxicity assessment of this trial
suggests that the Minnie Pearl Regimen should include a
carboplatin dose with an AUC of 4 rather than 6, espe-
cially if subcutaneous amifostine is included as part of the
regimen.
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Table 3: Salient Grade 3 or Worse Adverse Events Attributed to Neoadjuvant Study Treatment
ADVERSE EVENT ABSOLUTE INCIDENCE NUMBER OF PATIENTS WITH EVENT
death (paclitaxel reaction) 1 1
neutropenia 11 9
leukopenia 12 10







electrolyte abnormalities 6 4
dyspnea 1 1
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